Nā huahana

ʻO ka mālama ʻana i nā cell mammalian me nā lāʻau chemotherapeutic hiki ke hopena i nā pilikia o nā loko nucleotide.ʻO ka nānā ʻana i kēia mau pilikia i loko o nā cell tumor moʻomeheu mai nā kumu kanaka he mea pono no ka loiloi i ka hopena o ka lāʻau lapaʻau a me ka hoʻomaopopo maikaʻi ʻana i ke ʻano o ka hana o kēia mau lāʻau lapaʻau.I loko o kēia haʻawina, ua hoʻohana ʻia ʻekolu papa o nā lāʻau chemotherapeutic me nā ʻano hana like ʻole i ka hoʻomohala ʻana i nā hiʻohiʻona cell i mālama ʻia i ka lāʻau.Ua hoʻokō ʻia ka LC-based metabolomics analysis of nucleotides in cell of the control group and the drug-treased group.Ua hui pū ʻia kekahi mau ʻano hana ʻikepili no ka ʻike ʻana i nā biomarkers e pili ana i ka hana o nā lāʻau lapaʻau, me ka nānā ʻana i hoʻokahi ala o ka ʻano like ʻole, ka nānā ʻana i nā mea nui, a me nā ʻāpana ʻano hana.ʻO ka mea kupanaha, hiki ke hoʻokaʻawale ʻia nā ʻāpana tumor o ka pūʻulu hoʻomalu a me nā hui i mālama ʻia i ka lāʻau, a ua ʻike ʻia kekahi mau ʻano like ʻole he potentia l biomarkers, e like me ATP, GMP, a me UDP no nā mea antimetabolite, ATP, GMP, a me CTP. no nā mea hoʻopōʻino DNA, a me GMP, ATP, UDP, a me GDP no nā mea hana spindle mitotic.ʻO ka hōʻoia hou ʻana o nā biomarkers hiki ke hana ʻia me ka hoʻohana ʻana i ka pihi hiʻona hana.Ke noʻonoʻo nei i kā lākou wahi kūpono ma lalo o ka pihi, ʻoi aku ka nui ma mua o 0.9, hiki ke hoʻoholo ʻia ʻo GMP a me ATP nā mea biomarkers maikaʻi loa no nā lāʻau hōʻino DNA, a me GMP, ATP, a me UDP no nā papa ʻelua o nā lāʻau lapaʻau.ʻAʻole hiki i kēia ala nucleotide palena ke hoʻokaʻawale loa i nā hana o nā lāʻau ʻeiwa, akā hāʻawi ia i nā hōʻike mua no ka hana o ka pharmacometabolomics i ka hoʻomohala preclinical o nā lāʻau lapaʻau.